Browse the evidence

Pre-exhaustion resistance training (single-joint immediately before multi-joint) does not produce superior muscle hypertrophy or strength gains compared to traditional resistance training and may result in slightly lower hypertrophy due to reduced volume load.

If your goal is maximum muscle growth, stick to traditional resistance training (performing all sets of one exercise before moving to the next). While pre-exhaustion (doing a single-joint exercise right before a compound one) is time-efficient and viable for strength and endurance, it likely results in slightly less muscle growth because you lift less total weight (volume load) on the compound movements due to fatigue. Do not sacrifice volume load on compound lifts for the sake of pre-fatiguing muscles if hypertrophy is your primary goal.

Pre-training bone characteristics (bone mineral content, bone area, shoulder/hip width) do not significantly predict the magnitude of appendicular lean tissue mass gains following 10–12 weeks of resistance training in untrained adults.

Do not worry about your bone structure or frame size when starting resistance training. Whether you have wide shoulders or narrow hips, your potential for muscle growth is not determined by your skeleton. Focus on consistent training with progressive overload (increasing weight/reps over time) and adequate protein intake, as these are the drivers of hypertrophy, not your baseline bone density or width.

Isoenergetic pre-exercise meals with varying carbohydrate content (high vs. low) do not improve resistance training volume performance compared to a low-calorie placebo in resistance-trained individuals.

If you are eating a pre-workout meal, the specific amount of carbohydrates matters less than the total calories and protein, provided you are already eating a moderate amount of carbs throughout the day. You do not need to force-feed high-carb meals before lifting to maximize volume; a lower-carb, isoenergetic meal works just as well.

Administration of BHB-Phe (50 mg/kg, IP) suppresses food intake and body weight in obese mice by activating distinct hypothalamic and brainstem neural populations, independent of melanocortin, GLP-1, or GDF15 pathways.

This research identifies a specific metabolite, BHB-Phe, which reduces food intake in obese mice. It works by activating specific brain regions, distinct from other known weight loss pathways. While the pathway is conserved in humans, direct efficacy in humans has not been established. Current BHB supplements do not necessarily provide this specific conjugate in bioavailable forms or doses shown to be effective in mice.

Adherence to macronutrient-restricted diets (low-carb or low-fat) is often inadequate, with many participants failing to meet the specified macronutrient targets, and energy intake often not differing between restricted and ad libitum groups.

Don't stress if you can't hit exact macronutrient targets. Most people in clinical trials don't either. Focus on sustainable habits rather than perfect adherence to specific numbers.

SGLT2 inhibitors reduce the risk of developing diabetes in high-risk patients with heart failure or chronic kidney disease.

If you have heart failure or kidney disease, even without diabetes, ask your doctor if an SGLT2 inhibitor is right for you. These drugs protect your heart and kidneys and may also prevent diabetes.

Bariatric surgery (RYGB, Sleeve Gastrectomy) significantly reduces long-term cardiovascular mortality and incidence of coronary heart disease, stroke, and myocardial infarction compared to non-surgical management.

For severe obesity, bariatric surgery is the most effective long-term treatment for preventing heart attacks, strokes, and death. It works by creating lasting metabolic changes and weight loss.

Minoritized racial and ethnic groups in the US Veterans Affairs healthcare system receive significantly less access to evidence-based obesity treatments (medications and bariatric surgery) compared to White patients, despite having universal insurance coverage.

If you are a minority veteran with obesity, do not assume insurance alone guarantees access to the best treatments. Proactively ask your provider about all options, including medications and surgery, and advocate for yourself if you feel you are being steered only toward lifestyle programs.

Minoritized patients are disproportionately funneled into lifestyle counseling (MOVE!) while being underutilized for more effective, intensive treatments like medications and bariatric surgery.

Be aware that you might be offered lifestyle programs first. While these are helpful, they are less effective than medications or surgery for many. Ask your provider why you are not being considered for more intensive treatments if your BMI and health status warrant it.

GLP-1 receptor agonists (Semaglutide, Tirzepatide) activate human hypothalamic POMC neurons via L-type calcium channels, causing sustained membrane depolarization and increased action potential firing.

GLP-1 drugs like Semaglutide work by directly activating specific neurons in your brain (POMC neurons) that suppress appetite. This activation is sustained and mediated by calcium channels, suggesting the brain plays a central role in the weight loss effects, not just stomach emptying.

Tirzepatide increases the risk of total adverse events (TAEs) and adverse events leading to discontinuation (DAEs) in a dose-dependent manner, with the 15mg dose having the highest risk.

Tirzepatide (TZP) comes with a higher risk of side effects, especially at the 15mg dose. These side effects, which often include gastrointestinal issues like nausea and vomiting, can lead to patients stopping the medication. The risk of these side effects increases with the dose. Patients with obesity may experience more side effects than those with T2DM. It is important to discuss these potential side effects with your doctor and monitor how your body responds to the medication.

A structured behavioral group intervention focusing on satiety and healthy eating habits ('Dare to feel full') does not produce superior long-term weight loss or metabolic improvements compared to a brief individual counseling session with standard dietary advice in overweight/obese adults.

For sustainable weight management, intensive group programs may not offer advantages over brief, personalized counseling. Focus on maintaining a healthy, varied diet and regular follow-up rather than seeking complex, time-intensive interventions.

Tirzepatide (5, 10, and 15 mg weekly) improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.

If you have moderate to severe fatty liver disease (MASH) with scarring (fibrosis), tirzepatide (5-15 mg weekly) can help resolve the liver inflammation and scarring in about 62% of patients at the highest dose, without making the scarring worse.

The adverse association between elevated BMI (>27 kg/m²) and mortality in HFrEF patients is significantly stronger in those with ischemic cardiomyopathy compared to non-ischemic cardiomyopathy.

If your heart failure is caused by coronary artery disease (ischemic), keeping your BMI under 27 is particularly important for your survival. In patients with non-ischemic heart failure, the link between higher BMI and death was not statistically significant in this study, suggesting that weight management strategies might need to be tailored to your specific heart condition.

Standardized multidisciplinary care and ERAS protocols reduce postoperative complications to ~1% and shorten hospital stays, improving overall safety and long-term outcomes.

Choosing a bariatric center that uses standardized protocols and multidisciplinary teams (surgeons, endocrinologists, psychologists) significantly lowers the risk of complications and shortens recovery time, leading to safer and more sustainable results.

Bariatric surgery (RYGB, Sleeve Gastrectomy) provides superior and more sustained weight loss (25-35%) and metabolic remission compared to pharmacotherapy, but carries higher surgical risks and potential for long-term complications.

Bariatric surgery (like gastric bypass or sleeve gastrectomy) is the most effective treatment for severe obesity, typically resulting in 25-35% weight loss. It offers significant improvements in diabetes and hypertension. However, it is invasive, carries surgical risks, and requires lifelong nutritional monitoring. It is generally recommended for those with BMI ≥ 40 or ≥ 35 with comorbidities who have not succeeded with other methods.

Leptin resistance is a common trait in obesity that impairs the feedback between fat mass and the hypothalamus, leading to dysregulated appetite and energy storage.

In obesity, the hormone leptin, which signals satiety, often stops working effectively (leptin resistance). This means the brain doesn't receive the 'stop eating' signal even when fat stores are high, contributing to continued overeating.

Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.

If you were recently diagnosed with high blood sugar, ask your doctor about a short course of intensive insulin therapy (2-3 weeks). This 'reset' can restore your body's ability to manage blood sugar on its own, potentially allowing you to avoid lifelong medication.

Tirzepatide exposure does not significantly increase or decrease the risk of adverse cardiovascular events (myocardial infarction, coronary artery disease, heart failure, stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) in participants with type 2 diabetes or obesity compared to control groups.

For patients with T2DM or obesity, current evidence from multiple randomized trials indicates that tirzepatide does not significantly increase or decrease the risk of major cardiovascular events (like heart attack or stroke) or specific renal adverse events (like kidney stones or UTIs) compared to other treatments or placebo. While long-term safety in high-risk groups requires more data, short-to-medium term use appears safe regarding these specific outcomes.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide reduce adipocyte size and promote the browning of white adipose tissue (WAT) by upregulating thermogenic genes (e.g., UCP1) and activating the AMPK/SIRT1 pathway, thereby shifting adipose tissue function from energy storage to energy expenditure.

If you are taking a GLP-1 medication like semaglutide or liraglutide, understand that it is actively remodeling your fat tissue. It shrinks fat cells and activates 'browning' processes that burn energy, which is a key part of why these drugs are effective for long-term metabolic health, beyond just reducing your appetite.

Combining tirzepatide with leptin produces synergistic weight loss and improved metabolic homeostasis in diet-induced obesity models, driven by reduced food intake and increased energy expenditure.

For individuals with obesity who have leptin resistance, adding leptin to tirzepatide treatment may enhance weight loss and metabolic health beyond what tirzepatide achieves alone. This synergy works by reducing food intake and increasing energy expenditure, suggesting that combination therapies targeting multiple hormonal pathways can overcome resistance mechanisms.

GLP-1 receptor agonist therapy is associated with significant gastrointestinal adverse events and weight regain upon discontinuation, limiting its long-term durability compared to surgery.

GLP-1 medications like semaglutide or liraglutide can help you lose 15-25% of your body weight, but you may experience nausea, vomiting, or digestive issues. Crucially, if you stop taking the medication, you are likely to regain the weight. Surgery offers more sustained weight loss and cardiovascular protection, though it involves surgical risks.

Resmetirom (THR-β agonist) improves biopsy-confirmed MASH resolution and fibrosis without causing significant weight loss, acting through a lipid-centric mechanism.

If you have MASH, resmetirom is a daily pill that targets liver fat and inflammation directly. It works even if you don't lose weight, making it a distinct option from weight-loss drugs.

Using GLP-1 receptor agonists for weight loss results in higher social stigma and lower willingness to affiliate compared to losing weight through diet and exercise, and is stigmatized even more than remaining at a higher weight without attempting weight loss.

If you use GLP-1s for weight loss, be aware that you may face significant social judgment, potentially more than if you stayed at your current weight. This stigma stems from perceptions that medication is an 'easy shortcut' compared to diet and exercise. This social penalty can undermine the psychological benefits of weight loss and may discourage continued treatment. It is important to seek support and understand that this stigma is a social bias, not a reflection of your health efforts.